Covid19
Conditions
Keywords
Ivermectin, SARS-CoV-2, Coronavirus, Prophylaxis, PrEP, Covid-19
Brief summary
This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).
Interventions
Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
Sponsors
Grupo Rescue S.A.S República Dominicana
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC) during the study.
Exclusion criteria
* Workers with positive Covid-19 RT-PCR prior to the start of the study * Those that did not take the first dose of Ivermectin the first week at the start of the study * Those that did not complied with at least 2 out of 4 weekly doses * Those that had greater than 14 days difference in days between two intakes Ivermectin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants RT-PCR positive for Covid-19 | 4 weeks | Workers confirmed Covid-19 through Reverse Transcription Polymerase Chain Reaction (RT-PCR) test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of sick participants who condition deteriorated | 4 weeks | Workers infected with Covid-19, confirmed with RT-PCR and required hospitalization and/or ICU |
| Number of sick participants who died | 4 weeks | Workers infected with Covid-19, confirmed with RT-PCR and died. |
Countries
Dominican Republic
Outcome results
None listed